{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T11:14:04Z","timestamp":1775301244162,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,12,7]],"date-time":"2018-12-07T00:00:00Z","timestamp":1544140800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1038\/s41409-018-0417-9","type":"journal-article","created":{"date-parts":[[2018,12,7]],"date-time":"2018-12-07T10:22:27Z","timestamp":1544178147000},"page":"1237-1244","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Real-life feasibility of salvage allogeneic transplantation in peripheral T-cell lymphomas"],"prefix":"10.1038","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4088-036X","authenticated-orcid":false,"given":"Alberto","family":"Mussetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicol\u00f2","family":"Martinetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicoletta","family":"Cieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Pennisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Dodero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Corradini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,12,7]]},"reference":[{"key":"417_CR1","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","volume":"117","author":"DD Weisenburger","year":"2011","unstructured":"Weisenburger DD, Savage KJ, Harris NL, Gascoyne RD, Jaffe ES, MacLennan KA. et al.Peripheral T-cell lymphoma, not otherwise specified: A report of 340 cases from the International Peripheral T-cell Lymphoma Project.Blood. 2011;117:3402\u20138.","journal-title":"Blood"},{"key":"417_CR2","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein Harald, Siebert R. et al.The 2016 revision to the World Health Organization (WHO) classification of lymphoid neoplasms.Blood. 2016;127:2375\u201390.","journal-title":"Blood"},{"issue":"suppl 5","key":"417_CR3","doi-asserted-by":"publisher","first-page":"v108","DOI":"10.1093\/annonc\/mdv201","volume":"26","author":"F. d'Amore","year":"2015","unstructured":"d\u2019Amore F, Gaulard P, Tr\u00fcmper L, Corradini P, Kim WS, Specht L, et al. Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015. Sep;26 Suppl 5:v108-15. https:\/\/doi.org\/10.1093\/annonc\/mdv201 .","journal-title":"Annals of Oncology"},{"key":"417_CR4","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","volume":"116","author":"N Schmitz","year":"2010","unstructured":"Schmitz N, Tr\u00fcmper L, Ziepert M, Nickelsen M, Ho AD, Metzner B. et al.Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group.Blood. 2010;116:3418\u201325.","journal-title":"Blood"},{"key":"417_CR5","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","volume":"31","author":"V Mak","year":"2013","unstructured":"Mak V, Hamm J, Chhanabhai M, Shenkier T, Klasa R, Sehn LH. et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: Spectrum of disease and rare long-term survivors. J Clin Oncol. 2013;31:1970\u20136.","journal-title":"J Clin Oncol"},{"key":"417_CR6","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1016\/j.bbmt.2017.07.027","volume":"23","author":"MA Kharfan-Dabaja","year":"2017","unstructured":"Kharfan-Dabaja MA, Kumar A, Ayala E, Hamadani M, Reimer P, Gisselbrecht C, et al. Clinical practice recommendations on indication and timing of hematopoietic cell transplantation in mature T cell and NK\/T cell lymphomas: an international collaborative effort on behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2017;23:1826\u201338. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879117306237 .","journal-title":"Biol Blood Marrow Transplant"},{"key":"417_CR7","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1200\/JCO.2004.12.050","volume":"22","author":"P Corradini","year":"2004","unstructured":"Corradini P, Dodero A, Zallio F, Caracciolo D, Casini M, Bregni M. et al.Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin\u2019s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol. 2004;22:2172\u20136.","journal-title":"J Clin Oncol"},{"key":"417_CR8","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/leu.2011.240","volume":"26","author":"A Dodero","year":"2012","unstructured":"Dodero A, Spina F, Narni F, Patriarca F, Cavattoni I, Benedetti F, et al. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed\/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia. 2012;26:520\u20136. http:\/\/www.nature.com\/articles\/leu2011240 .","journal-title":"Leukemia"},{"key":"417_CR9","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1365-2141.2010.08210.x","volume":"150","author":"AR Shustov","year":"2010","unstructured":"Shustov AR, Gooley TA, Sandmaier BM, Shizuru J, Sorror ML, Sahebi F. et al. Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas. Br J Haematol. 2010;150:170\u20138.","journal-title":"Br J Haematol"},{"key":"417_CR10","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1200\/JCO.2012.46.0188","volume":"31","author":"SM Smith","year":"2013","unstructured":"Smith SM, Burns LJ, van Besien K, LeRademacher J, He W, Fenske TS, et al. Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. J Clin Oncol. 2013;31:3100\u20139. https:\/\/doi.org\/10.1200\/JCO.2012.46.0188 .","journal-title":"J Clin Oncol"},{"key":"417_CR11","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","volume":"84","author":"NL Harris","year":"1994","unstructured":"Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361\u201392. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8068936 .","journal-title":"Blood"},{"key":"417_CR12","unstructured":"Jaffe ES, Harris, NS WHO Classification Tumors of Hematopoietic and Lymphoid Tissues. (Eds.) Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H. Lyon Thiele J, France; IARC Publication 2001."},{"key":"417_CR13","doi-asserted-by":"crossref","unstructured":"International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med. 1993;329:987\u201394.","DOI":"10.1056\/NEJM199309303291402"},{"key":"417_CR14","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","volume":"103","author":"A Gallamini","year":"2004","unstructured":"Gallamini A. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103:2474\u20139. https:\/\/doi.org\/10.1182\/blood-2003-09-3080 .","journal-title":"Blood"},{"key":"417_CR15","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. J Clin Oncol. 1999;17:1244\u20131244. https:\/\/doi.org\/10.1200\/JCO.1999.17.4.1244 .","journal-title":"J Clin Oncol"},{"key":"417_CR16","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579\u201386. https:\/\/doi.org\/10.1200\/JCO.2006.09.2403 .","journal-title":"J Clin Oncol"},{"key":"417_CR17","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628\u201333. http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879109003231","journal-title":"Biol Blood Marrow Transplant"},{"key":"417_CR18","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912\u20139. https:\/\/doi.org\/10.1182\/blood-2005-05-2004 .","journal-title":"Blood"},{"key":"417_CR19","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J. et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"417_CR20","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/0002-9343(80)90380-0","volume":"69","author":"HM Shulman","year":"1980","unstructured":"Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204\u201317. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/6996481 .","journal-title":"Am J Med"},{"key":"417_CR21","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1111\/bjh.14477","volume":"176","author":"D Chihara","year":"2017","unstructured":"Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, et al. The survival outcome of patients with relapsed\/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. Br J Haematol. 2017;176:750\u20138. https:\/\/doi.org\/10.1111\/bjh.14477 .","journal-title":"Br J Haematol"},{"issue":"S1","key":"417_CR22","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1038\/bmt.2012.282","volume":"48","author":"S Iacobelli","year":"2013","unstructured":"Iacobelli S. Suggestions on the use of statistical methodologies in studies of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2013;48(S1):S1\u201337. http:\/\/www.nature.com\/articles\/bmt2012282 .","journal-title":"Bone Marrow Transplant"},{"key":"417_CR23","unstructured":"StataCorp. Stata Statistical Software: Release 13. College Station, TX: StataCorp LP; 2013."},{"key":"417_CR24","unstructured":"R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2013. ISBN 3-900051-07-0 U http:\/\/www. R org\/."},{"key":"417_CR25","doi-asserted-by":"publisher","first-page":"4771","DOI":"10.1182\/blood-2008-10-183723","volume":"113","author":"A Dodero","year":"2009","unstructured":"Dodero A, Carniti C, Raganato A, Vendramin A, Farina L, Spina F, et al. Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery. Blood. 2009;113:4771\u20139. https:\/\/doi.org\/10.1182\/blood-2008-10-183723 .","journal-title":"Blood"},{"key":"417_CR26","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.exphem.2005.05.009","volume":"33","author":"A Dodero","year":"2005","unstructured":"Dodero A, Carrabba M, Milani R, Rizzo E, Raganato A, Montefusco V. et al. Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed. Exp Hematol. 2005;33:920\u20137.","journal-title":"Exp Hematol"},{"key":"417_CR27","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1200\/JCO.2007.14.1366","volume":"26","author":"S Gouill Le","year":"2008","unstructured":"Le Gouill S, Milpied N, Buzyn A, Peffault De Latour R, Vernant J-P, Mohty M, et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Mo\u00eblle et de Th\u00e9rapie Cellulaire. J Clin Oncol. 2008;26:2264\u201371. https:\/\/doi.org\/10.1200\/JCO.2007.14.1366 .","journal-title":"J Clin Oncol"},{"key":"417_CR28","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1200\/JCO.2008.20.4628","volume":"27","author":"C Kyriakou","year":"2009","unstructured":"Kyriakou C, Canals C, Finke J, Kobbe G, Harousseau J-L, Kolb H-J, et al. Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2009;27:3951\u20138. https:\/\/doi.org\/10.1200\/JCO.2008.20.4628 .","journal-title":"J Clin Oncol"},{"key":"417_CR29","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/s41409-018-0116-6","volume":"53","author":"YT Hsu","year":"2018","unstructured":"Hsu Y-T, Tsai H-J, Chang JS, Li S-S, Tang J-L, Yeh S-P, et al. Stem cell transplantation for T-cell lymphomas in Taiwan. Bone Marrow Transplant. 2018;53:993\u20131000. http:\/\/www.nature.com\/articles\/s41409-018-0116-6 .","journal-title":"Bone Marrow Transplant"},{"key":"417_CR30","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.3324\/haematol.2017.186577","volume":"103","author":"M Bellei","year":"2018","unstructured":"Bellei M, Foss FM, Shustov AR, Horwitz SM, Marcheselli L, Kim WS, et al. The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project. Haematol. 2018;103:1191\u20137. https:\/\/doi.org\/10.3324\/haematol.2017.186577 .","journal-title":"Haematol"},{"key":"417_CR31","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1007\/s00277-018-3288-7","volume":"97","author":"S Rohlfing","year":"2018","unstructured":"Rohlfing S, Dietrich S, Witzens-Harig M, Hegenbart U, Sch\u00f6nland S, Luft T. et al. The impact of stem cell transplantation on the natural course of peripheral T-cell lymphoma: a real-world experience. Ann Hematol. 2018;97:1241\u201350.","journal-title":"Ann Hematol"},{"key":"417_CR32","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","volume":"30","author":"B Pro","year":"2012","unstructured":"Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Brentuximab Vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30:2190\u20136. https:\/\/doi.org\/10.1200\/JCO.2011.38.0402 .","journal-title":"J Clin Oncol"},{"key":"417_CR33","doi-asserted-by":"publisher","unstructured":"Gambacorti Passerini C, Farina F, Stasia A, Redaelli S, Ceccon M, Mologni L, et al. Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase\u2013positive lymphoma patients. J Natl Cancer Inst. 2014;106. https:\/\/doi.org\/10.1093\/jnci\/djt378","DOI":"10.1093\/jnci\/djt378"},{"key":"417_CR34","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/annonc\/mdq359","volume":"22","author":"G Gutierrez-Garcia","year":"2011","unstructured":"Gutierrez-Garcia G, Garcia-Herrera A, Cardesa T, Martinez A, Villamor N, Ghita G, et al. Comparison of four prognostic scores in peripheral T-cell lymphoma. Ann Oncol. 2011;22:397\u2013404. https:\/\/doi.org\/10.1093\/annonc\/mdq359 .","journal-title":"Ann Oncol"},{"key":"417_CR35","doi-asserted-by":"publisher","first-page":"4019","DOI":"10.1200\/JCO.2017.73.8195","volume":"35","author":"MJ Maurer","year":"2017","unstructured":"Maurer MJ, Ellin F, Srour L, Jerkeman M, Bennani NN, Connors JM, et al. International assessment of event-free survival at 24 months and subsequent survival in peripheral T-cell lymphoma. J Clin Oncol. 2017;35:4019\u201326. https:\/\/doi.org\/10.1200\/JCO.2017.73.8195 .","journal-title":"J Clin Oncol"},{"key":"417_CR36","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1200\/JCO.2013.51.5866","volume":"32","author":"MJ Maurer","year":"2014","unstructured":"Maurer MJ, Ghesqui\u00e8res H, Jais J-P, Witzig TE, Haioun C, Thompson CA, et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol. 2014;32:1066\u201373. https:\/\/doi.org\/10.1200\/JCO.2013.51.5866 .","journal-title":"J Clin Oncol"},{"key":"417_CR37","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","volume":"376","author":"M Hallek","year":"2010","unstructured":"Hallek M, Fischer K, Fingerle-Rowson G, Fink A, Busch R, Mayer J, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376:1164\u201374. http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673610613815","journal-title":"Lancet"},{"key":"417_CR38","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","volume":"33","author":"C Casulo","year":"2015","unstructured":"Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol. 2015;33:2516\u201322. https:\/\/doi.org\/10.1200\/JCO.2014.59.7534 .","journal-title":"J Clin Oncol"},{"key":"417_CR39","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1200\/JCO.2015.65.4194","volume":"34","author":"G Hapgood","year":"2016","unstructured":"Hapgood G, Zheng Y, Sehn LH, Villa D, Klasa R, Gerrie AS, et al. Evaluation of the risk of relapse in classical hodgkin lymphoma at event-free survival time points and survival comparison with the general population in British Columbia. J Clin Oncol. 2016;34:2493\u2013500. https:\/\/doi.org\/10.1200\/JCO.2015.65.4194 . Available from","journal-title":"J Clin Oncol"},{"key":"417_CR40","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1038\/leu.2016.147","volume":"30","author":"N Majithia","year":"2016","unstructured":"Majithia N, Rajkumar SV, Lacy MQ, Buadi FK, Dispenzieri A, Gertz MA, et al. Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents. Leukemia. 2016;30:2208\u201313. http:\/\/www.nature.com\/articles\/leu2016147 .","journal-title":"Leukemia"},{"key":"417_CR41","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1093\/annonc\/mdu515","volume":"26","author":"M Loirat","year":"2015","unstructured":"Loirat M, Chevallier P, Leux C, Moreau A, Bossard C, Guillaume T, et al. Upfront allogeneic stem-cell transplantation for patients with nonlocalized untreated peripheral T-cell lymphoma: an intention-to-treat analysis from a single center. Ann Oncol. 2015;26:386\u201392. https:\/\/academic.oup.com\/annonc\/article\/26\/2\/386\/2800589 .","journal-title":"Ann Oncol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41409-018-0417-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-018-0417-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-018-0417-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T10:20:07Z","timestamp":1775298007000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-018-0417-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,7]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["417"],"URL":"https:\/\/doi.org\/10.1038\/s41409-018-0417-9","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,7]]},"assertion":[{"value":"10 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}